Kunihiro Sasahara - Concepedia

Author

Kunihiro Sasahara

Daiichi-Sankyo (Japan)

Also Known As

KUNIHIRO SASAHARA, Kunihiro SASAHARA, Kunihiro Sasahara

Publications

491

Citations

H-Index

Concepts

All Affiliations

Daiichi-Sankyo (Japan)

About

Kunihiro Sasahara is an author at Daiichi-Sankyo (Japan) specializing in pharmacology, medicine, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	345
2	Health Sciences	3	3	68
3	Engineering	1	1	16
4	Natural Sciences	1	1	67
5	Social Sciences	1	1	11

Kunihiro Sasahara

Publications

468

Citations

H-Index

Page 1

	Year	Citations
Improved delivery through biological membranes. 4. Prodrugs of L-DOPA Nicholas Bodor, Kenneth B. Sloan, Takeru Higuchi, Journal of Medicinal Chemistry PharmacotherapyBiological MembranesExperimental PharmacologyMedicinal ChemistryPharmacological Study	1977	67
Dosage form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients Kunihiro Sasahara, Takashi Nitanai, Taeko Habara, Journal of Pharmaceutical Sciences Dosage Form DesignMarketed Levodopa PreparationsPharmacologyNeuropharmacologyClinical Pharmacology	1980	44
Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors Tomokatsu Hori, K Muraoka, Yoshikazu Saito, Journal of neurosurgery Tumor InnervationPharmacotherapyHigh-grade GliomasMetronomic ChemotherapyGlioma	1987	42
Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs. Minoru Sekine, HIDENARI TERASHIMA, Kunihiro Sasahara, Journal of Pharmacobio-Dynamics	1985	41
Stereoselective pharmacokinetics of RS‐8359, a selective and reversible MAO‐A inhibitor, by species‐dependent drug‐metabolizing enzymes Wataru Takasaki, Mayumi Yamamura, Akiko Nozaki, Chirality	2005	37
Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients Kunihiro Sasahara, Takashi Nitanai, Taeko Habara, Journal of Pharmaceutical Sciences Dosage Form DesignPharmacological StudyMedicineLevodopa IiiParkinsonian Patients	1980	35
Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs Kunihiro Sasahara, Takashi Nitanai, Taeko Habara, Journal of Pharmaceutical Sciences Dosage Form DesignPharmacological StudyMedicineLevodopa IvPharmacotherapy	1981	33
An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry Kiyoshi Kawabata, Nobuko Matsushima, Kunihiro Sasahara Biomedical Chromatography	1998	32
Dosage form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs Kunihiro Sasahara, Takashi Nitanai, Taeko Habara, Journal of Pharmaceutical Sciences Dosage Form DesignGastrointestinal PharmacologyIntestinal SegmentsMedicineLevodopa V	1981	30
Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up Yoshihiro Mitsuhashi, Yuichi Sugiyama, Shogo Ozawa, Cancer Chemotherapy and Pharmacology Animal PhysiologyVeterinary PhysiologyMedicinePhysiologyLaboratory Animal Study	1990	16

Page 1